NSE: COHANCE · 11 November 2026
- Cohance Lifesciences Ltd. (COHANCE) shares advanced 3.00% today, trading near the upper end of a ₹441.25 to ₹465.95 intraday range after opening at ₹445.00.
- Cohance Lifesciences announced that the United States Food and Drug Administration issued the Establishment Inspection Report for its manufacturing facility located at Pashamylaram, Hyderabad. The regulatory agency classified the inspection outcome as Voluntary Action Indicated, effectively concluding the inspection process.
- Trading volume was 0.57 times the 20-day average daily volume.
Why is Cohance Lifesciences share price rising on 11 November 2026?
Cohance Lifesciences Ltd. (COHANCE) shares advanced 3.00% today, trading near the upper end of a ₹441.25 to ₹465.95 intraday range after opening at ₹445.00.
The broader market exhibited positive momentum, with the benchmark Nifty gaining 1.23%, while the thematic Nifty Pharma sector index slipped 0.52%. Cohance outperformed both the broader market and its sector peers, building on a 5-day return of 3.77% and a prior session return of 2.33%, though it remains down 1.19% over the past two trading days.
Recent sentiment continues to draw context from the company's fiscal second-quarter updates released earlier in November, where management reported a sequential revenue recovery of 12.90% quarter-on-quarter to ₹4,767 million and an adjusted EBITDA margin improvement to 10% from 2% in the previous quarter. Additionally, the company announced that the USFDA issued an Establishment Inspection Report for its Pashamylaram manufacturing facility, classifying the outcome as Voluntary Action Indicated and formally concluding the inspection.
4.26 lakh shares traded by 11 November 2026 · 10:30 AM IST. This compares with a 20-day average daily volume of 7.49 lakh shares (0.57 times). The five-day average daily volume was 5.17 lakh shares. Separately, the NSE report for 9 November 2026 showed 3.17 lakh shares delivered, representing 35.57% of that day’s traded volume. The same report recorded 32,467 trades.
The 3.00% gain aligns with recent operational recovery reported in Q2 earnings and the successful closure of the USFDA inspection at the Pashamylaram plant, supported by recent positive return momentum.
Latest Company Developments
Cohance Lifesciences announced that the United States Food and Drug Administration issued the Establishment Inspection Report for its manufacturing facility located at Pashamylaram, Hyderabad. The regulatory agency classified the inspection outcome as Voluntary Action Indicated, effectively concluding the inspection process.
Successful conclusion of the inspection clears regulatory overhang regarding this key manufacturing facility.
The company submitted its unaudited financial results for the quarter and half year ended September 30, 2026. Q2 operating revenue reached ₹4,767 million, reflecting a 12.90% sequential recovery alongside an adjusted EBITDA of ₹458 million and an adjusted profit after tax of ₹75 million.
Provides baseline earnings data demonstrating sequential operational recovery from a weaker preceding quarter.
Cohance released its revised investor presentation detailing segment performance across Pharma CDMO, API+, and specialty chemicals, alongside strategic integration progress. Management indicated that the second half of fiscal 2027 is expected to be stronger than the first half, supported by improved order visibility and small molecule deliveries.
Offers forward-looking visibility into management's revenue and margin recovery expectations for the remainder of the fiscal year.
Cohance Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Appointment of Mr Abhimanyu Ojha as Chief Financial Officer of the company effective. October 12, 2026.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 16.93% on 30 September 2026. This compares with 18.21% on 30 June 2026, a change of -1.28 percentage points.
The filing reported 25 MF/UTI holders.
Historical Bulk / Block Deals
What to Watch Next
- Execution of stronger H2 order book and small molecule deliveries
- Progress on integration of Sapala and One Cohance platform initiatives
- Further developments regarding capital allocation and planned capex investments
- Sustained delivery volume participation above the 20-day average
Other Dated Coverage
More Cohance Lifesciences news and dated analysis →
Frequently Asked Questions
What is the latest Cohance Lifesciences company news?
Cohance Lifesciences announced that the United States Food and Drug Administration issued the Establishment Inspection Report for its manufacturing facility located at Pashamylaram, Hyderabad. The regulatory agency classified the inspection outcome as Voluntary Action Indicated, effectively concluding the inspection process.
How strong was Cohance Lifesciences’s trading volume?
4.26 lakh shares traded, 0.57 times the 20-day average daily volume. The price and volume data are dated 11 November 2026 · 10:30 AM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.